Truist raises Vericel stock price target on MACI growth momentum
Truist Securities raised its price target for Vericel (VCEL) to $65 from $52, citing strong Q3 results and growth momentum in its MACI product line. The company reported record surgeon additions, biopsies, and implants, along with upside in its Burn Care segment. VCEL's stock surged 28.6% in the past week, trading near its 52-week high. The company posted 25.3% revenue growth over the last twelve months with a 74.5% gross profit margin.
How this was made
The 30-second read
Why it matters
The earnings beat and higher target are likely to drive short‑term buying interest and could set a new price floor.
Market read
The news provides a fresh catalyst for VCEL, with potential spillover to the broader med‑tech sector.
What to watch
Potential regulatory or reimbursement risks for MACI products are not addressed in the article.
Background
Vericel reported Q3 2026 results with strong earnings and revenue growth, prompting Truist to raise its price target.
Ticker impact
Truist raised Vericel's price target to $65 after the company reported Q3 earnings that beat expectations with $0.27 EPS and 25% revenue growth.
likely upward pressure as investors price in the new target and strong growth outlook
The combination of a 350% EPS beat, revenue growth, and a 25% price target increase provides a clear catalyst for buying pressure.
Market effects
Positive earnings may lift other small‑cap med‑tech stocks as investors seek growth exposure.
U.S. small‑cap biotech sector could see modest gains.
Limited to U.S. listed med‑tech niche.
Counterpoint
If the growth assumptions prove unsustainable, the stock could face a pull‑back after the initial rally.
Key entities
- companyVericel Corporation
NASDAQ‑listed med‑tech firm focused on MACI and Burn Care products.
- analystTruist Securities
Investment bank that raised the price target.
